patented technology to grow and expand adult Stem Cells

Adult stem cell development company commencing clinical trials applicable to estimated $30 billion degenerative disease market place

Free
Message: Zacks now rates PSTI as a "strong buy"

Ron, it would be interesting to know the projected price of the report you describe. I can tell you that the Point and Figure Charts on StockCharts.com give a bullish projected price target of $8.75. That has been in place for many months and there is no time frame of when it will achieve that price target. I find that encouraging. BioTech is getting a lot of attention these days and I think the sector will soon start a bull run, all my opinion of course. PSTI is in the right place at the right time with validated patents!

Share
New Message
Please login to post a reply